OBJECTIVE: To explore the role of indoleamine-pyrrole 2,3-dioxygenase (IDO), an immunomodulatory enzyme, in renal cell carcinoma (RCC). METHODS: A total of 40 patients diagnosed as RCC in the Second Xiangya Hospital were included in this study. All patients received nephrectomy. The histopathological features of samples were assessed semi-quantitatively. IDO mRNA level in RCC and non-RCC renal tissues was determined by real-time quantitative PCR (RT-qPCR). And the expression of IDO protein in endothelial cells was examined by immunohistochemistry; a Kaplan-Meier survival curves was calculated on the basis of IDO mRNA level. RESULTS: Level of IDO mRNA in RCC samples was significantly higher than that in tumor-free samples with P<0.001. Patients with high IDO expression had an significantly longer survival time than those with low IDO expression (P=0.01). There was a statistically significant inverse correlation between IDO and proliferation marker Ki67. Patients with high IDO level were of low Ki67 level, and vice versa (P<0.01). CONCLUSION: IDO might be a prognostic biomarker for patients with RCC.
OBJECTIVE: To explore the role of indoleamine-pyrrole 2,3-dioxygenase (IDO), an immunomodulatory enzyme, in renal cell carcinoma (RCC). METHODS: A total of 40 patients diagnosed as RCC in the Second Xiangya Hospital were included in this study. All patients received nephrectomy. The histopathological features of samples were assessed semi-quantitatively. IDO mRNA level in RCC and non-RCC renal tissues was determined by real-time quantitative PCR (RT-qPCR). And the expression of IDO protein in endothelial cells was examined by immunohistochemistry; a Kaplan-Meier survival curves was calculated on the basis of IDO mRNA level. RESULTS: Level of IDO mRNA in RCC samples was significantly higher than that in tumor-free samples with P<0.001. Patients with high IDO expression had an significantly longer survival time than those with low IDO expression (P=0.01). There was a statistically significant inverse correlation between IDO and proliferation marker Ki67. Patients with high IDO level were of low Ki67 level, and vice versa (P<0.01). CONCLUSION:IDO might be a prognostic biomarker for patients with RCC.
Authors: A Marijne Heeren; Ilse van Dijk; Daniella R A I Berry; Maryam Khelil; Debbie Ferns; Jeroen Kole; René J P Musters; Victor L Thijssen; Constantijne H Mom; Gemma G Kenter; Maaike C G Bleeker; Tanja D de Gruijl; Ekaterina S Jordanova Journal: Front Immunol Date: 2018-07-11 Impact factor: 7.561
Authors: Lukas Lanser; Patricia Kink; Eva Maria Egger; Wolfgang Willenbacher; Dietmar Fuchs; Guenter Weiss; Katharina Kurz Journal: Front Immunol Date: 2020-02-21 Impact factor: 7.561